-31.7%
CPRT vs MRNA
+27.9%
-59.6%
-57.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.0% | +0.7% | -4.7% | -4.0% |
| 7D | -8.4% | -8.2% | -0.2% | -8.1% |
| 30D | +4.6% | +125.6% | -121.0% | -2.3% |
| 3M | -1.9% | +197.1% | -199.0% | -9.6% |
| 6M | -15.3% | +148.5% | -163.8% | -21.4% |
| YTD | -21.5% | +363.3% | -384.7% | -29.4% |
| 1Y | -36.6% | +462.0% | -498.6% | -43.7% |
| All | -31.7% | +27.9% | -59.6% | -38.2% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling